{
    "root": "f124fad5-1e6a-4161-bc98-2b927e2df5d2",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "Tretinoin",
    "value": "20250301",
    "ingredients": [
        {
            "name": "TRETINOIN",
            "code": "5688UTC01R"
        },
        {
            "name": "BUTYLATED HYDROXYANISOLE",
            "code": "REK4960K2U"
        },
        {
            "name": "EDETATE DISODIUM",
            "code": "7FLD91C86K"
        },
        {
            "name": "GELATIN",
            "code": "2G86QN327L"
        },
        {
            "name": "GLYCERIN",
            "code": "PDC6A3C0OX"
        },
        {
            "name": "MEDIUM-CHAIN TRIGLYCERIDES",
            "code": "C9H2L21V7U"
        },
        {
            "name": "NITROGEN",
            "code": "N762921K75"
        },
        {
            "name": "FERRIC OXIDE RED",
            "code": "1K09F3G675"
        },
        {
            "name": "SOYBEAN OIL",
            "code": "241ATL177A"
        },
        {
            "name": "LECITHIN, SOYBEAN",
            "code": "1DI56QDM62"
        },
        {
            "name": "ALCOHOL",
            "code": "3K9958V90M"
        },
        {
            "name": "TITANIUM DIOXIDE",
            "code": "15FIX9V2JP"
        },
        {
            "name": "YELLOW WAX",
            "code": "2ZA36H0S2V"
        },
        {
            "name": "FERRIC OXIDE YELLOW",
            "code": "EX438O2MRT"
        }
    ],
    "indications": "tretinoin capsules indicated induction remission adults pediatric patients 1 year age older acute promyelocytic leukemia ( apl ) characterized presence ( 15 ; 17 ) translocation pml/rarα gene expression , refractory relapsed anthracycline chemotherapy anthracycline-based chemotherapy contraindicated .",
    "contraindications": "recommended tretinoin capsules 22.5 mg/m 2 orally twice daily complete remission . ( 2.2 ) discontinue 30 days achievement complete remission 90 days treatment , whichever occurs first . ( 2.2 )",
    "warningsAndPrecautions": "tretinoin capsules supplied 10 mg capsules , two-tone ( lengthwise ) reddish-brown opaque yellow gelatin shell , imprinted “ tr ” black ink yellow side . supplied high-density polyethylene , opaque bottles 100 capsules available : 100 count bottles child-resistant closure ndc 10370-268-01 store 20ºc 25ºc ( 68ºf 77ºf ) ; [ usp controlled room temperature ] . keep bottle tightly closed . protect light .",
    "adverseReactions": "tretinoin capsules contraindicated patients known hypersensitivity tretinoin capsules , components , retinoids . included rash , pruritus , face edema , dyspnea [ ( 6.1 ) ] .",
    "indications_original": "Tretinoin capsules are indicated for the induction of remission in adults and pediatric patients 1 year of age and older with acute promyelocytic leukemia (APL) characterized by the presence of the t(15;17) translocation or PML/RARα gene expression, and who are refractory to or who have relapsed from anthracycline chemotherapy or for whom anthracycline-based chemotherapy is contraindicated.",
    "contraindications_original": "The recommended dosage of tretinoin capsules is 22.5 mg/m 2 orally twice daily until complete remission. ( 2.2 ) Discontinue 30 days after achievement of complete remission or after 90 days of treatment, whichever occurs first. ( 2.2 )",
    "warningsAndPrecautions_original": "Tretinoin capsules are supplied as 10 mg capsules, two-tone (lengthwise) with reddish-brown opaque and yellow gelatin shell, imprinted with “TR” with black ink on the yellow side. Supplied in high-density polyethylene, opaque bottles of 100 capsules available in:\n                  \n                     100 count bottles with child-resistant closure                         NDC 10370-268-01\n                  \n                  Store at 20ºC to 25ºC (68ºF to 77ºF); [see USP Controlled Room Temperature].\n                  Keep bottle tightly closed. Protect from light.",
    "adverseReactions_original": "Tretinoin capsules are contraindicated in patients with a known hypersensitivity to tretinoin capsules, any of its components, or other retinoids. Reactions have included rash, pruritus, face edema, and dyspnea [see Adverse Reactions (6.1)]."
}